The Pseudovax trial featured on national television

Before the Christmas break, the major Norwegian TV channel TV2 visited the Radium Hospital to learn about the Pseudovax trial. The first patient that recived the vaccine, Mette, was the main focus, together with comments from general secretary Ingrid Stenstadvold Ross in the Norwegian Cancer Society and Kjersti Flatmark, one of the lead investigators of the study.
The Pseudovax clinical trial will evaluate a novel cancer vaccine developed at the Norwegian Radium Hospital specifically for patients with Pseudomyxoma peritonei (PMP) .
"If the vaccine proves to be effective, we hope that this could become an new treatment option for patients with PMP who are not cured by surgery", Flatmark says.



